Parkinson's

Extracted Attributes

• Disease Type

  Neurodegenerative disorder

• Risk Factors

  Age, male sex, genetics (first-degree relatives), and exposure to toxins (herbicides/pesticides)

• Non-Motor Symptoms

  Autonomic dysfunction, sleep disturbances, anosmia (loss of smell), cognitive impairment, and anxiety

• Average Age of Onset

  Approximately 70 years old

• Standard Medications

  Levodopa, dopamine agonists, and MAO-B inhibitors

• Early-Onset Threshold

  Before age 50

• Surgical Intervention

  Deep brain stimulation (DBS)

• Pathological Hallmarks

  Loss of dopamine-producing neurons in the substantia nigra; presence of Lewy bodies (alpha-synuclein clumps)

• Primary Motor Symptoms

  Tremors, bradykinesia (slowness of movement), rigidity, and postural instability

Timeline

• Publication of research regarding orally inhaled levodopa (CVT-301) for treating OFF periods in Parkinson's disease. (Source: Mayo Clinic)

  2019-03-26

• Publication of research on Istradefylline as a first-generation adenosine A2A antagonist for PD treatment. (Source: Mayo Clinic)

  2021-02-11

• Publication of study exploring personalized medicine and new options for advanced Parkinson's treatments. (Source: Mayo Clinic)

  2021-07-01

• Documented access date for clinical guidelines on the initial pharmacologic treatment of Parkinson's disease. (Source: Mayo Clinic)

  2024-04-08

Parkinson's disease

Parkinson's disease (PD), or simply Parkinson's, is a neurodegenerative disease primarily of the central nervous system, affecting both motor and non-motor systems. The motor symptoms, collectively called parkinsonism, include tremors, slowness in initiating movement (bradykinesia), rigidity, and difficulty maintaining balance (postural instability). Non-motor symptoms such as autonomic nervous system failures (dysautonomia), sleep abnormalities, decreased ability to smell (anosmia), and behavioral changes or neuropsychiatric problems, such as cognitive impairment, psychosis, and anxiety, may appear at any stage of the disease. Symptoms typically develop gradually and non-motor issues become more prevalent as the disease progresses. Parkinson's disease has no single cause: rather, genetic and environmental factors interact to affect critical cellular processes. Parkinson's disease involves the gradual decay and loss of dopamine-producing neurons in a brain region called the substantia nigra and other related cell groups in the brainstem. Misfolded proteins, such as alpha-synuclein, aggregate to form clumps called Lewy bodies, if not cleared from cells by cellular degradation systems. Protein accumulation stimulates the release of pro-inflammatory molecules by the microglia, a protective response that can cause neuroinflammation, further neuronal damage, and disruption of metabolic systems, if remaining chronic. Diagnosis is primarily based on signs and symptoms, typically motor-related, identified through neurological examination. Medical imaging techniques such as PET scanning can support the diagnosis. PD typically manifests in individuals over 60, with about one percent affected. In those younger than 50, the condition is termed "early-onset PD". No cure for PD is known, and treatment focuses on alleviating symptoms. Initial treatment typically includes levodopa, MAO-B inhibitors, or dopamine agonists. As the disease progresses, these medications become less effective and may cause involuntary muscle movements. Diet and rehabilitation therapies can help improve symptoms. Deep brain stimulation is used to manage severe motor symptoms when drugs are ineffective. Little evidence exists for treatments addressing non-motor symptoms, such as sleep disturbances and mood instability. Life expectancy for those with PD is near-normal, but is decreased for early-onset.

Web Search Results

• Parkinson's disease - Wikipedia

  Parkinson's disease has no single cause: rather, genetic and environmental factors interact to affect critical cellular processes. Parkinson's disease involves the gradual decay and loss of dopamine-producing neurons in a brain region called the substantia nigra and other related cell groups in the brainstem. Misfolded proteins, such as alpha-synuclein, aggregate to form clumps called Lewy bodies, if not cleared from cells by cellular degradation systems. Protein accumulation stimulates the release of pro-inflammatory molecules by the microglia, a protective response that can cause neuroinflammation, further neuronal damage, and disruption of metabolic systems, if remaining chronic. [...] [edit] See also: Parkinsonism and Parkinson-plus syndrome Parkinson's disease is a neurodegenerative disease affecting both the central and peripheral nervous systems, characterized by the loss of dopamine-producing neurons in the substantia nigra region of the brain. It is classified as a synucleinopathy due to the abnormal accumulation of the protein alpha-synuclein, which aggregates into Lewy bodies within affected neurons. [...] Parkinson's disease has no single cause: rather, genetic and environmental factors interact and affect critical cellular processes in a complex interplay. Parkinson's disease (PD) involves the gradual degeneration of dopamine producing neurons in a brain region called the substantia nigra and other related cell groups in the brainstem. This is accompanied by the accumulation of misfolded proteins such as alpha-synuclein. Alpha-synuclein is normally found in the presynaptic terminals of neurons. If alpha-synuclein is mis-folded and not cleared from cells by cellular degradation systems, it can build up to form clumps of proteins called Lewy bodies and Lewy neurites. Accumulation stimulates the release of pro-inflammatory molecules by the microglia, a protective response that can cause

• Parkinson's 101 | Parkinson's Disease - Michael J. Fox Foundation

  ### What Is Parkinson's Disease? Parkinson’s disease (PD) occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die. Because PD can cause tremor, slowness, stiffness, and walking and balance problems, it is called a “movement disorder.” But constipation, depression, memory problems and other non-movement symptoms also can be part of Parkinson’s. PD is a lifelong and progressive disease, which means that symptoms slowly worsen over time. [...] Researchers believe that in most people, Parkinson's is caused by a combination of environmental and genetic factors. Certain environmental exposures, such as pesticides and head injury, are associated with an increased risk of PD. Still, most people have no clear exposure that doctors can point to as a straightforward cause. The same goes for genetics. Certain genetic mutations are linked to an increased risk of PD. But in the vast majority of people, Parkinson’s is not directly related to a single genetic mutation. Learning more about the genetics of Parkinson’s is one of our best chances to understand more about the disease and discover how to slow or stop its progression. [...] #### What Is Parkinson's Disease? Dr. Rachel Dolhun, a movement disorder specialist and vice president of medical communications at The Michael J. Fox Foundation, breaks down the basics of Parkinson's. ## What Causes Parkinson's Disease? Researchers believe that in most people, Parkinson's is caused by a combination of environmental and genetic factors. ## How Is Parkinson’s Diagnosed? Doctors use your medical history and physical examination to diagnose Parkinson's disease (PD). No blood test, brain scan or other test can be used to make a definitive diagnosis of PD. ## What Are the Symptoms? The symptoms of Parkinson’s and their degree of severity are different for every person. ## How Is Parkinson’s Treated?

• Parkinson's disease - Symptoms and causes - Mayo Clinic

  Risk factors Risk factors for Parkinson's disease include: Age. The risk of Parkinson's disease increases with age. Usually, it starts around age 50 or older. The average age of onset is around age 70. Parkinson's disease can occur in younger adults, but it is rare. When people younger than age 50 have the disease, it's known as early-onset Parkinson's disease. Genetics. Having one or more first-degree relatives, such as parents or siblings, with Parkinson's disease increases your risk. Your risks are still small unless you have many blood relatives with the condition. Male sex. Men are more likely to develop Parkinson's disease than are women. Exposure to toxins. Ongoing exposure to herbicides and pesticides may slightly increase your risk of Parkinson's disease. [...] 15. Spindler MA, et al. Initial pharmacologic treatment of Parkinson disease. Accessed April 8, 2024. 16. Hauser RA, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. Parkinsonism and Related Disorders. 2019; doi:10.1016/j.parkreldis.2019.03.026. 17. Mishima T, et al. Personalized medicine in Parkinson's disease: New options for advanced treatments. Journal of Personalized Medicine. 2021; doi:10.3390/jpm11070650. 18. Jenner P, et al. Istradefylline — A first generation adenosine A2A antagonist for the treatment of Parkinson's disease. Expert Review of Neurotherapeutics. 2021; doi:10.1080/14737175.2021.1880896. [...] The presence of Lewy bodies. Clumps of proteins in the brain are associated with Parkinson's disease. These are called Lewy bodies, and researchers believe these proteins hold an important clue to the cause of Parkinson's disease. Alpha-synuclein found within Lewy bodies. Alpha-synuclein is a protein found in all Lewy bodies. It occurs in a clumped form that cells can't break down. This is currently an important focus among Parkinson's disease researchers. Alpha-synuclein has been found in the spinal fluid of people who later have Parkinson's disease.

• What to Know About Managing Parkinson's Disease | News

  ## 1. What is Parkinson’s disease, and how does it develop? Parkinson’s disease is a degenerative brain condition that causes a variety of symptoms, notably uncontrollable movements, including shaking, stiffness, trouble with coordination and balance, and cognitive difficulties. It’s a progressive condition affecting nearly 1 million Americans that worsens over time, although this can vary from one person to another. And although Parkinson’s alone is not a fatal condition, it can lead, over time, to conditions or issues that are life-threatening and/or fatal.

• What is Parkinson's Disease | APDA

  ### Symptoms of Parkinson’s Parkinson’s disease symptoms vary widely among individuals, presenting a unique combination of motor and non-motor signs. The hallmark symptoms include tremors, stiffness, and slowness of movement, impacting daily activities and quality of life. Additionally, non-motor symptoms such as sleep disturbances, mood changes, and cognitive challenges are increasingly recognized for their significant impact. Early identification and management of these symptoms are crucial for improving patient outcomes. Parkinson’s disease symptoms ### Causes of Parkinson’s

• Instance Of

  Q4167410